home / stock / etnb / etnb news

ETNB News and Press, 89bio Inc. From 11/03/21

Stock Information
Company Name: 89bio Inc.
Stock Symbol: ETNB
Market: NYSE
Website: 89bio.com
Menu
ETNB ETNB Quote ETNB Short ETNB News ETNB Articles ETNB Message Board
Get ETNB Alerts

News, Short Squeeze, Breakout and More Instantly...
ETNB - 89bio Announces Appointment of Kathy LaPorte to its Board of Directors

SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy...
ETNB - 89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD's The Liver Meeting 2021

SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that a sub-analysis of i...

ETNB - 89bio to Participate in the Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s M...

ETNB - 89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s M...
ETNB - 89bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Initiated Phase 2b ENLIVEN trial in NASH patients - - Completed enrollment in NASH histology cohort with topline data expected by year-end 2021 - SAN FRANCISCO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused o...

ETNB - 89bio completes enrollment in BIO89-100 NASH study

89bio (NASDAQ:ETNB) announces that it has completed target enrollment of 20 patients in the paired-biopsy, open-label histology cohort in biopsy-confirmed fibrosis stage F2 – F3 NASH patients. The key efficacy endpoints include a 2-point or greater improvement in the NAFLD Activity Sco...

ETNB - 89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH

SAN FRANCISCO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has completed ta...
ETNB - 89bio: Undervalued Contender In Race For First NASH Drug Approval

89bio has an engineered FGF21 targeting therapy - BIO89-100 - in development for NASH and SHTG. NASH is a "holy grail" disease target, and a host of companies are competing to deliver the first ever approved drug. BIO89-100 is not winning the race, but its data compares with any l...

ETNB - Galectin Therapeutics, ReShape Lifesciences leads healthcare gainers; Sigilon Therapeutics, Aerpio Pharmaceuticals among major losers

Gainers: Galectin Therapeutics GALT +40%, ReShape Lifesciences (RSLS) +21%, INmune Bio (INMB) +17%, ASLAN Pharmaceuticals (ASLN) +15%, 89bio (ETNB) +14%.Losers: Sigilon Therapeutics SGTX -30%, Aerpio Pharmaceuticals (ARPO) -14%, Alterity ...

ETNB - 89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Ma...
Previous 10 Next 10